

Supplementary Table SI. Sequences of siRNA, shRNA, and primers.

Name	Sequence (5' → 3')	GenBank Accession #	Target position
NC-siRNA			
Sense	UUCUCCGAACGUGUCACGUTT		Scramble
Antisense	ACGUGACACGUUCGGAGAATT		
RBM15-siRNA-1			
Sense	CGCGGAAUACAAGACUCUGAA	NM_022768.5	nt 527-547
Antisense	UUCAGAGUCUUGUAUUCGCG		
RBM15-siRNA-2			
Sense	GAUCGUUACAACAGCGACAAU	NM_022768.5	nt 2073-2093
Antisense	AUUGUCGCUGUUGUAACGAUC		
RBM15-siRNA3			
Sense	GAGACUACCCGUUCUAUGA	NM_022768.5	nt 1021-1039
Antisense	UCAUAGAACGGGUAGUCUC		
NC-shRNA			
Sense	ccggTTCTCCGAACGTGTCACGTCTCGA GACGTGACACGTTCGGAGAATTTTTg		Scramble
Antisense	aattcAAAAAATTCTCCGAACGTGTCACG TCTCGAGACGTGACACGTTCGGAGAA		
RBM15-shRNA			
Sense	ccggAAGAGACTACCCGTTCTATGACTC GAGTCATAGAACGGGTAGTCTCTTTTT TTg	NM_022768.5	nt 1021-1039
Antisense	aattcAAAAAAGAGACTACCCGTTCTA TGACTCGAGTCATAGAACGGGTAGTC TCTT		
RBM15 primer			
Forward	TGAGTTCTCCAGCAGTTCC	NM_022768.5	nt 2807-2826
Reverse	GGTCAGCGCCAAGTTTTCTC		nt 2954-2935
MDR1 primer			
Forward	CATTTGGCAAAGCTGGAGAG	NM_000927.5	nt 2792-2811
Reverse	ATCATTGGCGAGCCTGGTAG		nt 2928-2909
MDR1 m ⁶ A primer			
Forward	CCTCAGTCAAGTTCAGAGTC	NM_000927.5	nt 4422-4441
Reverse	CTATGATTCTCTCCACTTGATG		nt 4504-4482
β-actin primer			
Forward	TCATCACCATTGGCAATGAG	NM_001101.5	nt 824-843
Reverse	CACTGTGTTGGCGTACAGGT		nt 978-959

NC, negative control; si, small interfering; sh, short hairpin; nt, nucleotide; RBM15, RNA binding motif protein 15; MDR1, multidrug resistance 1. Lowercase letters indicate a linker.

Supplementary Table SII. Correlation between clinicopathological features and RBM15 expression in OC tumor tissues.

Characteristic	RBM15 expression		P-value
	High	Low	
n	22	17	
Age, years, mean \pm SD	53.91 \pm 9.22	55.12 \pm 9.14	0.686 ^a
T stage, n (%)			0.306 ^b
T1	3 (7.7%)	4 (10.3%)	
T2	4 (10.3%)	6 (15.4%)	
T3	15 (38.5%)	7 (17.9%)	
N stage, n (%)			0.725 ^b
N0	15 (38.5%)	13 (33.3%)	
N1	7 (17.9%)	4 (10.3%)	
M stage, n (%)			0.056 ^b
M0	17 (43.6%)	17 (43.6%)	
M1	5 (12.8%)	0 (0%)	
FIGO stage, n (%)			0.045 ^b
Stage I+II	5 (12.8%)	10 (25.6%)	
Stage III+IV	17 (43.6%)	7 (17.9%)	
Histology, n (%)			1.000 ^b
EC	4 (10.3%)	4 (10.3%)	
HGSC	9 (23.1%)	7 (17.9%)	
LGSC	8 (20.5%)	6 (15.4%)	
CCC	1 (2.6%)	0 (0%)	
CA125 (kU/L), median (IQR)	74.38 (53.95, 84.31)	64.07 (47.24, 68.27)	0.036 ^c
HE4 (pmol/L), median (IQR)	285.00 (241.40, 323.32)	228.30 (219.60, 346.00)	0.528 ^c
Recurrence, n (%)			0.045 ^b
Yes	17 (43.6%)	7 (17.9%)	
No	5 (12.8%)	10 (25.6%)	

Statistical tests: ^aStudent's t-test; ^bFisher test; ^cWilcoxon test. Italicized values represent statistically significant difference. OC, ovarian cancer; T, primary tumor; N, lymph node; M, metastasis; FIGO, International Federation of Gynaecological Oncologists; EC, endometrioid carcinoma; HGSC, high-grade serous carcinoma; LGSC, low-grade serous carcinoma; CCC, clear cell carcinoma; CA125, cancer antigen 125; HE4, human epididymis protein 4; IQR, interquartile range; n, number of cases; SD, standard deviation.